Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28488097 | 0.98 | ALDH1A1 (0.66) | ALDH1A1TSHREPHX2HSD17B10P2RX7 | |
| SCHEMBL13556180 | 0.94 | ALDH1A1 (0.61) | ALDH1A1TSHREPHX2HSD17B10P2RX7 | |
| SCHEMBL18624772 | 0.85 | ALDH1A1 (0.59) | ALDH1A1TSHREPHX2HSD17B10P2RX7 | |
| Hydrochloric Acid SCHEMBL17186360 | 0.83 | ALDH1A1 (0.58) | ALDH1A1TSHREPHX2HSD17B10P2RX7 | |
| SCHEMBL6158162 | 0.83 | ALDH1A1 (0.61) | ALDH1A1TSHREPHX2HSD17B10P2RX7 | |
| SCHEMBL2290939 | 0.81 | ALDH1A1 (1.00) | ALDH1A1TSHREPHX2HSD17B10P2RX7 | |
| SCHEMBL1239130 | 0.80 | EPHX2 (0.56) | ALDH1A1TSHREPHX2P2RX7L3MBTL1 | |
| SCHEMBL5889272 | 0.79 | ALDH1A1 (0.57) | ALDH1A1TSHREPHX2HSD17B10P2RX7 | |
| SCHEMBL11495581 | 0.79 | ALDH1A1 (0.68) | ALDH1A1TSHREPHX2HSD17B10P2RX7 | |
| Iodide SCHEMBL1714835 | 0.79 | EPHX2 (0.54) | ALDH1A1TSHREPHX2P2RX7L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458868-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-111848494-B | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230219896-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-13 | — | — | US | disclosed |
| US-11155521-B2 | Cannabinoid receptor mediating compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-10-26 | — | — | US | disclosed |
| CN-111848494-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10787419-B2 | Cannabinoid receptor mediating iminopyrazole compounds | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-09-29 | — | — | US | disclosed |
| US-10683270-B2 | Cannabinoid receptor mediating compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190352268-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2019-11-21 | — | — | US | disclosed |
| US-20180022705-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022706-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-01-25 | — | — | US | disclosed |
| US-9765031-B2 | Cannabinoid receptor mediating compounds | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| CN-106458868-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2017-02-22 | — | — | CN | disclosed |
| WO-2016196646-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMET OF HEALTH & HUMAN SERVICES (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20160257654-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160039766-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH E SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVI (US) | 2016-02-11 | — | — | US | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
| WO-2014078309-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219896-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | CNR1, CNR2, GPR18 | ALDH1A1 3508/4885TSHR 606/4885EPHX2 1009/4885 |
| US-10787419-B2 | Cannabinoid receptor mediating iminopyrazole compounds | CNR1, CNR2, GPR18 | ALDH1A1 3326/4885TSHR 810/4885EPHX2 1782/4885 |
| US-20180022705-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | CNR1, CNR2, GPR18 | ALDH1A1 3508/4885TSHR 606/4885EPHX2 1009/4885 |
| US-10683270-B2 | Cannabinoid receptor mediating compounds | CNR1, CNR2, GPR18 | ALDH1A1 3508/4885TSHR 606/4885EPHX2 1009/4885 |
| US-20190352268-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | CNR1, CNR2, GPR18 | ALDH1A1 3508/4885TSHR 606/4885EPHX2 1009/4885 |
| US-20160257654-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | CNR1, CNR2, GPR18 | ALDH1A1 3880/4885TSHR 611/4885EPHX2 1148/4885 |
| US-20180022706-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | CNR1, CNR2, GPR18 | ALDH1A1 3508/4885TSHR 606/4885EPHX2 1009/4885 |
| US-20160039766-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | CNR1, CNR2, GPR18 | ALDH1A1 3508/4885TSHR 606/4885EPHX2 1009/4885 |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | ALDH1A1 1471/4885TSHR 4596/4885EPHX2 4391/4885 |
| US-11155521-B2 | Cannabinoid receptor mediating compounds | CNR1, CNR2, GPR18 | ALDH1A1 3880/4885TSHR 611/4885EPHX2 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.